Skip to main content

Table 2 Adjusted hazard ratios and 95% confidence intervals of BMI and CMD for mortality in breast and colorectal cancer patients by stage at diagnosis

From: Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study

   BMI (continuous, per 1 kg/m2) CMD (reference: no CMD)
  n Adjusted for CMD HR (95%-CI) P-value (LR test) Adjusted for BMI HR (95%-CI) p-value (LR test)
Colorectal cancer
All stages 1045 No 1.06 (1.02–1.10)*   No 1.25 (0.97–1.61)  
   Yes 1.06 (1.02–1.09)* 0.065 Yes 1.22 (0.94–1.57) 0.002*
Localised 532 No 1.10 (1.04–1.17)*   No 1.73 (1.15–2.59)*  
   Yes 1.11 (1.04–1.18)* 0.031* Yes 1.76 (1.17–2.66)* 0.002*
Advanced 513 No 1.03 (0.99–1.08)   No 1.17 (0.83–1.64)  
   Yes 1.03 (0.98–1.07) 0.683 Yes 1.12 (0.80–1.59) 0.213
Breast cancer
All stages 1620 No 1.04 (1.00–1.08)*   No 1.46 (1.01–2.09)*  
   Yes 1.04 (1.00–1.08)* 0.069 Yes 1.42 (0.99–2.05) 0.135
Localised 1032 No 1.07 (1.01–1.13)*   No 1.38 (0.78–2.46)  
   Yes 1.07 (1.01–1.13)* 0.371 Yes 1.31 (0.74–2.35) 0.009*
Advanced 588 No 1.01 (0.96–1.07)   No 1.51 (0.95–2.42)  
   Yes 1.01 (0.96–1.07) 0.103 Yes 1.51 (0.94–2.41) 0.513
  1. Cox proportional regression stratified by sex (for colorectal cancer), age and country and adjusted for smoking, physical activity, alcohol consumption and education
  2. BMI: Predicted mean body mass index between age 20 and 50, continuous
  3. CMD: Diagnosis of cardiometabolic diseases including myocardial infraction, stroke or type 2 diabetes
  4. P-values of likelihood ratio tests (LR test) comparing models that include CMD in addition to BMI with models including only BMI / comparing models that include BMI in addition to CMD with models including only CMD
  5. *Statistically significant on a significance-level of p <  = 0.05